Sarcoidosis Clinical Trials

Find Sarcoidosis Clinical Trials Near You

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults subjects

• Cutaneous sarcoidosis with characteristic skin biopsy histology

• A CSAMI activity score ≥ 10

• Weight \> 40 kg to \< 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2.

Locations
United States
California
Clinical Trial Site
RECRUITING
San Francisco
North Carolina
Clinical Trial Site
RECRUITING
Durham
Pennsylvania
Clinical Trial Site
RECRUITING
Philadelphia
Wisconsin
Clinical Trial Site
RECRUITING
Madison
Contact Information
Primary
Clinical Trial Administrator
clinicaltrials@priovant.com
(212) 634-9743
Time Frame
Start Date: 2025-04-09
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 168
Treatments
Experimental: Part 1: Brepocitinib Dose Level 1
Oral Brepocitinib
Experimental: Part 1: Brepocitinib Dose Level 2
Oral Brepocitinib
Placebo_comparator: Part 1: Placebo
Experimental: Part 2: Brepocitinib Dose Level 1
Oral Brepocitinib
Placebo_comparator: Part 2: Placebo
Related Therapeutic Areas
Sponsors
Leads: Priovant Therapeutics, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.